We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Anastrozole (Arimidex) — non-steroidal aromatase inhibitor
A non-steroidal aromatase inhibitor (Arimidex) approved for hormone-receptor-positive breast cancer, where its evidence is strong (ATAC). Used off-label in men to block the testosterone-to-estradiol conversion — it reliably raises testosterone and lowers estradiol, which is why it's reached for in TRT and in obese hypogonadal men. The honest catch: estrogen is required for the male skeleton, so estrogen suppression lowers bone-mineral density and raises fracture risk, and the male-hypogonadism trials normalized hormones without improving strength or body composition. A prescription drug, not a supplement, and NOT a longevity drug.
Prescription medication — not a dietary supplement
Anastrozole is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Anastrozole doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2005–2026 with a typical study size of 69 participants.
Based on 35 studies · 4 meta-analyses · 29 RCTs · 7,867 total participants
Confidence
High confidenceBy outcome
Anastrozole has strong evidence in its approved indication (ATAC in breast cancer) and reliably raises testosterone and lowers estradiol in men, but the best randomized trials in hypogonadal men show it normalizes hormones without improving strength or body composition AND decreases bone-mineral density, a network meta-analysis found insufficient evidence in male infertility, and the male uses are entirely off-label — so the off-label men's-health case stays emerging.
141 trials ongoing or recruiting · 232 completed on ClinicalTrials.gov
99 of the completed trials have posted results
Registered trials show research momentum for Anastrozole, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Anastrozole is a potent, reversible, non-steroidal aromatase inhibitor that blocks the aromatase enzyme, which converts androgens (testosterone) into estrogens (estradiol).
Its approved, evidence-rich use is in postmenopausal hormone-receptor-positive breast cancer: the landmark ATAC trial established anastrozole as superior to tamoxifen for disease-free survival and recurrence, and it is a standard adjuvant therapy. Everything else is off-label.
In men, aromatase inhibition shifts the testosterone/estradiol balance — it reliably raises testosterone and lowers estradiol — which is why it is used off-label to treat hypogonadism (including obesity-driven hypogonadotropic hypogonadism, where excess adipose aromatase suppresses the gonadal axis), as an adjunct in some testosterone-therapy protocols to limit estrogen rise, and investigationally in male infertility and in pubertal boys with short stature (delaying bone-age advance to extend the growth window).
The crucial honesty gate: estrogen is not just a 'female' hormone — in men, estradiol is the dominant regulator of bone health and contributes to lipid and cardiovascular regulation.
The best randomized evidence in older hypogonadal men is sobering: anastrozole normalized testosterone and modestly lowered estradiol but did NOT improve body composition or muscle strength, and a one-year placebo-controlled trial showed it actually DECREASED spine bone-mineral density and did not improve skeletal health.
In breast cancer, the ATAC trial itself recorded more fractures on anastrozole than tamoxifen. A network meta-analysis found insufficient evidence to support aromatase inhibitors for male infertility.
So the male off-label case is mechanistically coherent (it moves the hormones the way intended) but clinically unproven for hard outcomes and carries a real, well-documented bone-density/fracture cost from estrogen suppression.
Anastrozole is a prescription drug; it is approved only for breast cancer, used off-label in men, and is NOT a longevity or healthspan drug.
The score reflects strong evidence in the approved oncology indication and reliable hormonal effects in men, set against unproven functional benefit off-label and a real bone-health trade-off.
Reversibly blocks the aromatase enzyme, which converts testosterone to estradiol — lowering estrogen and (in men) relieving estrogen's negative feedback on the gonadal axis.
Lower estradiol reduces negative feedback at the hypothalamus/pituitary, raising LH and FSH and thereby endogenous testosterone production in men.
Estradiol is the dominant regulator of male bone-mineral density and contributes to lipids; suppressing it lowers BMD and can nudge lipids — the central trade-off of the drug in men.
How Anastrozole works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Off-label and unproven for strength/body-composition benefit; monitor estradiol and bone — over-suppression harms the male skeleton.
Higher fracture risk — estrogen suppression worsens bone; weigh carefully and monitor DXA.
Specialist-only; monitor bone age, vertebral health, and lipids — long-term skeletal safety is not established.
Estrogens and estrogen-modulators counteract anastrozole's mechanism and reduce its efficacy.
Often co-prescribed to offset anastrozole-driven bone loss — clinically relevant interaction to plan around, not avoid.
Tip: Estrogen suppression lowers BMD in men and women; monitor DXA, ensure calcium/vitamin D, consider bone agents. Avoid over-suppressing estradiol in men.
Tip: A well-known aromatase-inhibitor effect; usually manageable, occasionally limits adherence.
Tip: Crashing estradiol in men harms libido and mood; keep E2 in a healthy range rather than as low as possible.
Tip: Estrogen withdrawal can cause flushing and modest lipid shifts; monitor lipids.
Anastrozole has an evidence score of 4.6/10 — emerging evidence based on 35 indexed studies, including 1 meta-analysis. A non-steroidal aromatase inhibitor (Arimidex) approved for hormone-receptor-positive breast cancer, where its evidence is strong (ATAC). Used off-label in men to block the testosterone-to-estradiol conversion — it reliably raises testosterone and lowers estradiol, which is why it's reached for in TRT and in obese hypogonadal men. The honest catch: estrogen is required for the male skeleton, so estrogen suppression lowers bone-mineral density and raises fracture risk, and the male-hypogonadism trials normalized hormones without improving strength or body composition. A prescription drug, not a supplement, and NOT a longevity drug. Representative study: PMID 39075435.
Dosing for Anastrozole: Approved breast-cancer dose is 1 mg once daily. Off-label use in men mirrors this (typically 0.5–1 mg/day or 1 mg 2–3×/week to avoid over-suppressing estradiol) under a clinician, with estradiol and bone monitoring. No cited trial used these lower or intermittent doses: the one cited trial in men gave 1 mg daily for 1 year to hypogonadal men aged 60 and over, and it did not improve body composition or strength. A prescription drug; not an approved men's-health regimen. Individual needs vary, so check the right dose for you with a healthcare provider.
Timing is flexible for Anastrozole — consistent daily use matters more than the time of day. Once daily (or intermittently for off-label men's use), with or without food.
Anastrozole should be used with caution — talk to a healthcare provider before taking it. Reported side effects include bone-density loss / increased fracture risk, joint / muscle aches (arthralgia), low libido / mood changes (men, from low estradiol). How often they occur is not established for all of them. Use caution if any of these apply to you: Premenopausal women / pregnancy (teratogenic; approved only postmenopausal); Pre-existing osteoporosis or high fracture risk (estrogen suppression worsens bone); Severe hepatic impairment.
Testosterone (TRT)
Too few graded studiesThe primary male androgen and a prescription medicine with US FDA-approved products for specified causes of male hypogonadism, and a Schedule III controlled substance in the US. For men with genuinely low testosterone, randomized trials show real benefits: the Testosterone Trials (TTrials) improved sexual function, mood, anemia and bone density in older hypogonadal men, and the large TRAVERSE trial found TRT non-inferior to placebo for major cardiac events. But those benefits were modest and indication-specific, NOT a longevity or anti-aging result. It is prescription-only in Germany and Austria. Non-medical, supraphysiologic and 'anti-aging' use is not established as safe or effective for longevity and carries serious harms — erythrocytosis, suppressed sperm production/fertility, cardiovascular and psychiatric risk. This is a harm-reduction reference, not a recommendation, and testosterone is NOT a dietary supplement.
Tamoxifen (Nolvadex)
Too few graded studiesA selective estrogen receptor modulator (SERM) and one of the most successful cancer drugs ever made: in estrogen-receptor-positive breast cancer, five years of adjuvant tamoxifen cuts 15-year recurrence by roughly half and breast-cancer death by about a third (EBCTCG), and it prevents breast cancer in high-risk women (NSABP P-1). Among men it is used OFF-LABEL — it antagonizes estrogen in breast tissue to prevent or treat gynecomastia (well-supported by RCTs during antiandrogen therapy, and in idiopathic/pubertal cases), and it blocks estrogen feedback at the hypothalamus to raise LH/FSH and endogenous testosterone, which is why it appears in male-infertility regimens and bodybuilding post-cycle therapy (PCT). The honest limits are real and non-negotiable: tamoxifen raises the risk of endometrial cancer and venous thromboembolism (clots, pulmonary embolism, stroke) and can cause visual/ocular changes. It is NOT a longevity drug.
Exemestane
Too few graded studiesA steroidal, irreversible ('suicide') aromatase inhibitor (Aromasin) approved for hormone-receptor-positive breast cancer, where its evidence is strong (the IES switch trial, MAP.3 prevention, and head-to-head with anastrozole in MA.27). It is the steroidal counterpart to anastrozole and letrozole, and because its metabolite is mildly androgenic it is sometimes claimed to spare bone — but the trials show it still lowers bone-mineral density and raises fracture risk. Used off-label in men to lower estradiol and raise testosterone, a small crossover RCT confirms it does shift the hormones, but estrogen is required for the male skeleton and lipids. A prescription drug, not a supplement, and NOT a longevity drug.
Clomiphene (Clomid)
Too few graded studiesA racemic selective estrogen receptor modulator (SERM) that has been FDA-approved for decades for female ovulation induction, and is used off-label in men with secondary (low-LH) hypogonadism to raise endogenous testosterone. By blocking estrogen feedback at the hypothalamus it increases LH and FSH, driving the testes to make more testosterone — unlike testosterone gels/injections, which suppress both. Honest appraisal: clomiphene is the RACEMIC mixture of enclomiphene (trans, the active estrogen-antagonist isomer) and zuclomiphene (cis, a long-lived weakly estrogenic isomer that accumulates) — the zuclomiphene downside is the entire reason the single-isomer enclomiphene was developed. Male use is off-label, the evidence is mostly observational and surrogate-based (testosterone/LH/FSH), and there are NO long-term hard-outcome trials. It is NOT a longevity drug.
Explore: Best supplements for Men's Health
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 35 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research